Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04561206 · ClinicalTrials.gov registry record · Phase 2
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
A Phase 2 study of Relapsed Classic Hodgkin Lymphoma, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 5
- Study locations
NCT04561206 is a Phase 2 study of Relapsed Classic Hodgkin Lymphoma that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 31 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT04561206, a Phase 2 study of Relapsed Classic Hodgkin Lymphoma, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Nivolumab is an antibody that enhances the immune system to better fight Hodgkin lymphoma cells. Giving brentuximab vedotin and nivolumab may be able to defer stem cell transplant treatment and spare the considerable cost and toxicity on transplantation.
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
- DRUG Brentuximab Vedotin
Study Locations (5)
California
- City of Hope Medical Center - Duarte
Illinois
- University of Chicago Cancer Research Center - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
New Jersey
- Hackensack University Medical Center/John Theurer Cancer Center - Hackensack
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2021-11-12 |
| Est. Completion | 2026-10-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04561206
The ClinicalTrials.gov registry entry for NCT04561206 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed Classic Hodgkin Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT04561206 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04561206 about?
NCT04561206 is a clinical study titled "Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma". This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuxima...
What is the current status of trial NCT04561206?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2021-11-12. Estimated completion is 2026-10-02.
What conditions does trial NCT04561206 study?
This clinical trial studies the following conditions: Relapsed Classic Hodgkin Lymphoma.
What interventions are being tested in trial NCT04561206?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Brentuximab Vedotin (DRUG).
Who is sponsoring clinical trial NCT04561206?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04561206 being conducted?
This trial has 5 study locations across California, Illinois, Massachusetts, New Jersey, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.